Some users are prescribed this option when stronger or more consistent results are needed
BLA for Rockets LAD-I Gene Therapy Under Review by FDA Again October 14, 2025 The FDA has accepted Rocket Pharmaceuticals resubmission of a BLA for marnetegragene autotemcel (RP-L201, to be marketed as Kresladi), a genetically modified autologous hematopoietic stem cell therapy intended to treat LAD-I
pAKK shows remarkable potential in combating Salmonella infections by upregulating intestinal barrier genes and secreting antimicrobial peptides (187)
Participants experienced average reductions in total cholesterol and LDL cholesterol, alongside improvements in blood pressure and glycaemic control
A fund that invests in Underlying ETFs may provide returns that are lower than the returns that an investor could achieve by investing in one or more Underlying ETFs alone and the fund bears its proportionate share of each ETFs expenses, subjecting fund shareholders to duplicative expenses
Preliminary research suggests it may influence incretin hormone pathways, though clinical evidence supporting meaningful GLP-1 or GIP enhancement in humans is lacking
